Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin Microdosing + Psychotherapy in TRD
NCT07183748Phase 2Recruiting
- Sponsor
- Be'er Sheva Mental Health Center
- Start
- Dec 2025
- Primary completion
- Jun 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in major depressive disorder (MDD), sponsored by Be'er Sheva Mental Health Center. Started Dec 2025; status: recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07183748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07183748.